---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-020209"
form_type: "8-K"
ticker: "NMRK"
cik: "0001690680"
company_name: "NEWMARK GROUP, INC."
filed_at: "2021-10-19T23:59:59+00:00"
generated_at: "2026-06-28T20:00:54.190873+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Chairman Howard Lutnick discloses Non-Hodgkin's Lymphoma diagnosis, expects full recovery in 4 months

## Summary
- Howard Lutnick diagnosed with highly treatable Non-Hodgkin's Lymphoma; expects to be cancer-free in 4 months.
- Treatment includes six chemotherapy sessions from Oct 18, 2021 through end of Jan 2022.
- Lutnick plans to continue serving as Chairman during treatment period.

## SEC filing metadata
- accession: 0001628280-21-020209
- form_type: 8-K
- ticker: NMRK
- cik: 0001690680
- company_name: NEWMARK GROUP, INC.
- filed_at: 2021-10-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690680/000162828021020209/0001628280-21-020209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690680/000162828021020209/nmrk-20211018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-020209
- JSON: https://secwatch.observer/filing/0001628280-21-020209.json
- Plain text: https://secwatch.observer/filing/0001628280-21-020209.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.